New Approach Enhances Treatment for Depression
MELBOURNE — Monash University has unveiled a new method for oral drug delivery, which may transform the treatment landscape for major depressive disorder. The announcement, made today, details a collaboration with Seaport Therapeutics that leverages fat absorption pathways to facilitate the oral delivery of previously injectable drugs.
According to the research published in Science Translational Medicine, this method involves a lipid-modified version of the neurosteroid allopregnanolone, known as GlyphAllo™, which can be effectively absorbed into the bloodstream when taken orally. This breakthrough could potentially offer a more accessible treatment for patients suffering from depression.
Clinical Trials and Implications
Professor Christopher Porter, Director of the Monash Institute of Pharmaceutical Sciences, emphasised the significance of this development, stating, “This technology finally unlocks the potential of allopregnanolone as an accessible daily treatment.” The research indicates that GlyphAllo successfully reduces stress response in clinical trials by lowering salivary cortisol levels when compared to a placebo.
The results come at a time of increasing demand for innovative treatments in mental health. The findings are being further explored in a Phase 2b trial named BUOY-1, aimed at evaluating GlyphAllo’s efficacy in adults with major depressive disorder. Dr. Michael Chen of Seaport Therapeutics highlighted the broader implications of the Glyph platform, noting its potential applications beyond neuropsychiatry, including oncology and metabolic diseases.
The implications of this research extend beyond the immediate benefits for depression treatment. By improving the oral delivery of drugs that were previously injectable, the technology could change how patients manage their conditions, potentially reducing the need for frequent doctor visits and allowing for better patient adherence to treatment regimens. This innovation may lead to similar breakthroughs in other areas of medicine, making drug administration more patient-friendly and accessible.
Source: newshub.medianet.com.au
Last updated: 29 June 2026, 12:41 pm
